Please login to the form below

Not currently logged in
Email:
Password:

cabozantinib

This page shows the latest cabozantinib news and features for those working in and with pharma, biotech and healthcare.

NICE clears Ipsen’s Cabometyx in first-line kidney cancer

NICE clears Ipsen’s Cabometyx in first-line kidney cancer

access cabozantinib earlier in their treatment pathway.”.

Latest news

  • Pfizer’s plans for Inlyta go awry with failed adjuvant trial Pfizer’s plans for Inlyta go awry with failed adjuvant trial

    nivolumab) and Exelixis’multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).

  • FDA’s year-end approvals take annual tally to 46 FDA’s year-end approvals take annual tally to 46

    Exelixis got the nod from the US regulator for Cabometyx (cabozantinib) as a first-line treatment for advanced renal cell carcinoma, giving the drug a boost against rival Sutent (sunitinib) from ... therapy. Analysts at Leerink have suggested the new

  • Ipsen’s liver cancer treatment clears phase III trial Ipsen’s liver cancer treatment clears phase III trial

    Ipsen and partner Exelixis are on track to file cancer treatment Cabometyx (cabozantinib) for a new liver cancer indication in the first half of next year, following positive phase III trial ... Data showed cabozantinib provided a ‘statistically

  • NICE gives green light to Ipsen's Cabometyx NICE gives green light to Ipsen's Cabometyx

    To date nearly 300 patients in the UK have benefited from cabozantinib through this Ipsen initiative, whilst the NICE process took place. ... We are delighted that now any eligible patient in the UK can benefit from cabozantinib.

  • Ipsen buys cancer business from stripped down Merrimack Ipsen buys cancer business from stripped down Merrimack

    For Ipsen, the deal continues its drive to expand its oncology franchise, currently headed by hormonal therapy Somatuline for neuroendocrine tumours and Cabometyx (cabozantinib) for advanced renal cell carcinoma.

More from news
Approximately 3 fully matching, plus 11 partially matching documents found.

Latest Intelligence

  • Accelerating innovation Accelerating innovation

    Meanwhile, 2016 saw a licensing deal with Cabometyx (cabozantinib) from Californian biotech Exelixis and an agreement with 3B Pharmaceuticals to develop novel oncology radiopharmaceuticals. ... Focusing on the future. In terms of its new oncology products

  • Charting a course for expansion Charting a course for expansion

    Cabometyx accelerates. Earlier this year Ipsen signed another deal to bolster its pipeline by harnessing external innovation, licensing promising cancer drug Cabometyx (cabozantinib) from Californian biotech Exelixis.

  • Deal Watch March 2016 Deal Watch March 2016

    marketed product Cometriq (cabozantinib). ... Collaboration – discovery, development &commercialisation. $965. Exelixis/ Ipsen. Cabozantinib (Renal Cell Carcinoma, Hepatocellular Carcinoma, other indications) and Cometriq (medullary thyroid cancer).

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 0 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Pegasus

Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics